Aprepitant Pellets
Aprepitant Pellets – NK1 Antagonist Pellets for Antiemetic Pharmaceutical Formulations. Rraynex Aprepitant Pellets are developed for pharmaceutical manufacturers producing antiemetic dosage forms requiring consistent pellet characteristics for capsule filling and multiparticulate processing.
Product overview
Aprepitant is an NK1 receptor antagonist used in antiemetic formulations. The pelletized platform supports formulation development where controlled particle size and reproducible capsule filling are important. Technical specifications are available upon request.
Key characteristics
- NK1 antagonist pellet platform.
- Controlled pellet morphology for capsule filling.
- Suitable for antiemetic formulation development.
- Support for scale-up and commercial manufacturing.
Product specifications
- Product
- Aprepitant Pellets
- Form
- Pellets
- Therapeutic category
- Neurokinin-1 Antagonist
- Available strengths
- 125 mg, 80 mg
- Grade
- IP / BP / USP / EP
- Pack size
- 25/50 kg
- Site certifications
- WHO-GMP, ISO 9001, ISO 14001
Detailed specifications, COA and technical documentation are shared on request.
Supply and enquiries
Rraynex supplies Aprepitant Pellets to pharmaceutical manufacturers, formulation developers and CDMOs in 25/50 kg packs with batch traceability. Send your quantity, grade and documentation needs through the enquiry form and the commercial team will reply with specifications and a quotation. Rraynex is a B2B supplier and does not sell to consumers.
Send product enquiry Browse all pellets Manufacturing capabilities
Other Aprepitant products from Rraynex
- Aprepitant (WW) — Pellets